The Alzheimer's Dementia Disease and Therapy Review provides incidence and prevalence numbers and percentages for major countries worldwide, information on diagnosis, and an overview of treatments. Dosing information and treatment costs are provided for Aricept, Namenda, Razadyne, and Exelon. General sales information is also included for these four products.

Additional Information

Disease and Therapy Reviews were developed to provide a basic understanding of the key facts about a disease and market in a quick, easy-to-read format. These reports are prepared by the senior market research team of Timely Data Resources. Each Disease and Therapy Review provides a concise analysis of the most important information about a particular disease, its treatment, and the market opportunities. Reports begin with an overview of the condition, and also contain tables that summarize the available worldwide incidence and prevalence data for the condition, a review of current diagnosis strategies and treatment options, general information about the market size, and information about important market trends. The data contained in these reports comes from key industry secondary data sources, such as the Timely Data Resources Incidence and Prevalence Database, and Lange's Current Medical Diagnosis and Treatment. This information is supplemented by reviews of analyst reports, company reports, and medical websites. Sources and references are provided.

I. Overview
II. Incidence and Prevalence
Incidence Table: (US, UK)
Prevalence Table: (US, Canada, UK, France, Italy, Japan, China, India, Worldwide)
III. diagnosis
IV. TREATMENT
V. DOSING
VI. TREATMENT COSTS
VI. MARKET SIZE
VII. COMMENTS
IX. References/Resources